Last reviewed · How we verify
Omega-3 Supplementation — Competitive Intelligence Brief
marketed
Dietary supplement / Lipid-modifying agent
GPR120, GPR40, PPAR-γ, NF-κB signaling pathway
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Omega-3 Supplementation (Omega-3 Supplementation) — Università degli Studi di Brescia. Omega-3 fatty acids reduce triglycerides and modulate inflammatory pathways by competing with arachidonic acid metabolism and inhibiting pro-inflammatory eicosanoid production.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Omega-3 Supplementation TARGET | Omega-3 Supplementation | Università degli Studi di Brescia | marketed | Dietary supplement / Lipid-modifying agent | GPR120, GPR40, PPAR-γ, NF-κB signaling pathway |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Dietary supplement / Lipid-modifying agent class)
- Università degli Studi di Brescia · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Omega-3 Supplementation CI watch — RSS
- Omega-3 Supplementation CI watch — Atom
- Omega-3 Supplementation CI watch — JSON
- Omega-3 Supplementation alone — RSS
- Whole Dietary supplement / Lipid-modifying agent class — RSS
Cite this brief
Drug Landscape (2026). Omega-3 Supplementation — Competitive Intelligence Brief. https://druglandscape.com/ci/omega-3-supplementation. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing